Array BioPharma Company Profile (NASDAQ:ARRY)

About Array BioPharma (NASDAQ:ARRY)

Array BioPharma logoArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARRY
  • CUSIP: 04269X10
  • Web: www.arraybiopharma.com
Capitalization:
  • Market Cap: $1.99 billion
  • Outstanding Shares: 171,442,000
Average Prices:
  • 50 Day Moving Avg: $9.34
  • 200 Day Moving Avg: $8.78
  • 52 Week Range: $3.45 - $13.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -29.00
  • P/E Growth: -1.14
Sales & Book Value:
  • Annual Revenue: $43.66 million
  • Price / Sales: 45.55
  • Book Value: $0.07 per share
  • Price / Book: 165.71
Profitability:
  • EBIDTA: ($100,010,000.00)
  • Net Margins: -77.44%
  • Return on Equity: -1,187.18%
  • Return on Assets: -47.96%
Debt:
  • Debt-to-Equity Ratio: 11.42%
  • Current Ratio: 3.88%
  • Quick Ratio: 3.88%
Misc:
  • Average Volume: 4.11 million shs.
  • Beta: 2.12
  • Short Ratio: 8.62
 

Frequently Asked Questions for Array BioPharma (NASDAQ:ARRY)

What is Array BioPharma's stock symbol?

Array BioPharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array BioPharma's earnings last quarter?

Array BioPharma Inc. (NASDAQ:ARRY) announced its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. The business earned $33.80 million during the quarter, compared to analyst estimates of $28.64 million. Array BioPharma had a negative return on equity of 1,187.18% and a negative net margin of 77.44%. The company's revenue for the quarter was down 21.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) earnings per share. View Array BioPharma's Earnings History.

When will Array BioPharma make its next earnings announcement?

Array BioPharma is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Array BioPharma.

Where is Array BioPharma's stock going? Where will Array BioPharma's stock price be in 2017?

7 brokerages have issued twelve-month price targets for Array BioPharma's stock. Their forecasts range from $9.00 to $18.00. On average, they expect Array BioPharma's stock price to reach $13.86 in the next year. View Analyst Ratings for Array BioPharma.

What are analysts saying about Array BioPharma stock?

Here are some recent quotes from research analysts about Array BioPharma stock:

  • 1. Cantor Fitzgerald analysts commented, "ARRY’s e-poster presentation of the safety lead in for the Phase III BEACON CRC study suggests that binimetinib/encorafenib could expand its market potential to colorectal cancer, which the shares do not currently reflect, in our view." (9/8/2017)
  • 2. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (8/11/2017)
  • 3. Cowen and Company analysts commented, "We see ARRY's decision to withdraw the NRAS NDA as prudent given the known modest efficacy benefit. The NRAS-mutant melanoma opportunity represented a modest 6% of our base model DCF, thus we lower our PT modestly from $15 to $14. We view recent share weakness and the passing of this 'risk' event as an especially attractive opportunity to firmly reiterate our Outperform rating on ARRY shares." (3/20/2017)

Are investors shorting Array BioPharma?

Array BioPharma saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 23,808,509 shares, an increase of 11.5% from the August 15th total of 21,357,969 shares. Based on an average daily trading volume, of 3,354,016 shares, the days-to-cover ratio is currently 7.1 days. Currently, 13.9% of the shares of the stock are sold short.

Who are some of Array BioPharma's key competitors?

Who are Array BioPharma's key executives?

Array BioPharma's management team includes the folowing people:

  • Kyle A. Lefkoff, Independent Chairman of the Board
  • Ron R. Squarer, Chief Executive Officer, Director
  • Jason Haddock, Chief Financial Officer
  • Andrew R. Robbins, Chief Operating Officer
  • Nicholas A. Saccomano Ph.D., Chief Scientific Officer
  • Curtis Oltmans, General Counsel
  • Victor Sandor, Chief Medical Officer
  • John R. Moore, Secretary
  • Shalini Sharp, Director
  • Charles M. Baum M.D., Ph.D., Independent Director

Who owns Array BioPharma stock?

Array BioPharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.49%), FMR LLC (10.85%), BlackRock Inc. (7.61%), State Street Corp (5.59%), POINT72 ASSET MANAGEMENT, L.P. Total Shares: 9,194,118 (5.40%) and Franklin Resources Inc. (5.24%). Company insiders that own Array BioPharma stock include Charles M Baum and Redmile Group, Llc. View Institutional Ownership Trends for Array BioPharma.

Who sold Array BioPharma stock? Who is selling Array BioPharma stock?

Array BioPharma's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Cambiar Investors LLC, Canada Pension Plan Investment Board, Bank of Nova Scotia, Columbus Circle Investors, Chicago Equity Partners LLC, Alliancebernstein L.P. and TD Asset Management Inc.. Company insiders that have sold Array BioPharma stock in the last year include Charles M Baum and Redmile Group, Llc. View Insider Buying and Selling for Array BioPharma.

Who bought Array BioPharma stock? Who is buying Array BioPharma stock?

Array BioPharma's stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Vanguard Group Inc., State Street Corp, Quantitative Investment Management LLC, Teachers Advisors LLC, Goldman Sachs Group Inc., Handelsbanken Fonder AB and First Trust Advisors LP. View Insider Buying and Selling for Array BioPharma.

How do I buy Array BioPharma stock?

Shares of Array BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Array BioPharma's stock price today?

One share of Array BioPharma stock can currently be purchased for approximately $11.60.


MarketBeat Community Rating for Array BioPharma (NASDAQ ARRY)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  371
MarketBeat's community ratings are surveys of what our community members think about Array BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Array BioPharma (NASDAQ:ARRY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $13.86 (19.46% upside)

Analysts' Ratings History for Array BioPharma (NASDAQ:ARRY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2017Piper Jaffray CompaniesReiterated RatingOverweight$14.00 -> $18.00LowView Rating Details
9/12/2017Jefferies Group LLCReiterated RatingBuy$9.00MediumView Rating Details
9/11/2017Cowen and CompanyReiterated RatingOutperform$14.00 -> $15.00HighView Rating Details
9/11/2017Cantor FitzgeraldBoost Price TargetOverweight$13.00 -> $15.00HighView Rating Details
9/11/2017Stifel NicolausReiterated RatingBuy -> Buy$13.00 -> $15.00HighView Rating Details
9/11/2017J P Morgan Chase & CoReiterated RatingBuy$14.00HighView Rating Details
1/30/2017Leerink SwannDowngradeOutperform -> Market Perform$11.00N/AView Rating Details
6/2/2016SunTrust Banks, Inc.Initiated CoverageBuy$7.00N/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Array BioPharma (NASDAQ:ARRY)
Earnings by Quarter for Array BioPharma (NASDAQ:ARRY)
Earnings History by Quarter for Array BioPharma (NASDAQ ARRY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017($0.23)N/AView Earnings Details
8/9/2017Q4 2017($0.21)($0.17)$28.64 million$33.80 millionViewListenView Earnings Details
5/10/2017Q3 2017($0.16)($0.21)$38.28 million$33.28 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.18)($0.14)$31.90 million$44.50 millionViewListenView Earnings Details
11/1/2016Q117($0.16)($0.20)$32.47 million$39.30 millionViewListenView Earnings Details
8/4/2016Q416($0.14)($0.17)$41.51 million$43.20 millionViewListenView Earnings Details
5/3/2016Q316($0.12)($0.16)$30.35 million$43.00 millionViewListenView Earnings Details
2/2/2016Q216($0.06)($0.17)$32.70 million$35.40 millionViewListenView Earnings Details
11/4/2015Q116($0.18)($0.15)$14.02 million$16.20 millionViewListenView Earnings Details
8/3/2015Q415($0.16)($0.09)$10.29 million$12.30 millionViewListenView Earnings Details
5/4/2015Q315($0.01)$0.37$6.00 million$6.60 millionViewListenView Earnings Details
2/3/2015Q215($0.20)($0.06)$10.20 million$26.92 millionViewListenView Earnings Details
11/4/2014Q115($0.22)($0.21)$6.35 million$6.07 millionViewListenView Earnings Details
8/12/2014Q414($0.23)($0.22)$8.10 million$6.00 millionViewListenView Earnings Details
4/29/2014Q314($0.21)($0.20)$9.40 million$7.80 millionViewListenView Earnings Details
2/4/2014Q214($0.16)($0.13)$13.49 million$14.10 millionViewListenView Earnings Details
10/31/2013Q114($0.18)($0.13)$11.20 million$14.20 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.13)($0.06)$16.13 million$25.40 millionViewListenView Earnings Details
5/6/2013Q3 2013($0.14)($0.19)$14.54 million$10.00 millionViewListenView Earnings Details
2/4/2013Q2 2013($0.14)($0.10)$16.52 million$18.40 millionViewListenView Earnings Details
10/29/2012Q113($0.15)($0.13)$16.70 million$15.80 millionViewN/AView Earnings Details
8/13/2012($0.11)($0.09)ViewN/AView Earnings Details
4/30/2012($0.16)($0.11)ViewN/AView Earnings Details
1/30/2012($0.12)($0.06)ViewN/AView Earnings Details
5/2/2011($0.25)($0.20)ViewN/AView Earnings Details
1/31/2011($0.28)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Array BioPharma (NASDAQ:ARRY)
2017 EPS Consensus Estimate: ($0.94)
2018 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.21)($0.22)
Q2 20173($0.27)($0.20)($0.22)
Q3 20173($0.31)($0.22)($0.25)
Q4 20173($0.29)($0.21)($0.25)
Q1 20182($0.31)($0.19)($0.25)
Q2 20182($0.32)($0.18)($0.25)
Q3 20182($0.36)($0.18)($0.27)
Q4 20182($0.26)($0.21)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Array BioPharma (NASDAQ:ARRY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Array BioPharma (NASDAQ:ARRY)
Insider Ownership Percentage: 3.18%
Institutional Ownership Percentage: 97.59%
Insider Trades by Quarter for Array BioPharma (NASDAQ:ARRY)
Institutional Ownership by Quarter for Array BioPharma (NASDAQ:ARRY)
Insider Trades by Quarter for Array BioPharma (NASDAQ:ARRY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/28/2017Charles M BaumDirectorSell25,000$9.27$231,750.00View SEC Filing  
9/28/2016Redmile Group, LlcMajor ShareholderSell2,492,578$6.36$15,852,796.08View SEC Filing  
9/15/2016Redmile Group, LlcMajor ShareholderBuy400,000$3.51$1,404,000.00View SEC Filing  
1/20/2016Redmile Group, LlcMajor ShareholderBuy300,000$3.19$957,000.00View SEC Filing  
1/12/2016Redmile Group, LlcMajor ShareholderBuy75,000$3.60$270,000.00View SEC Filing  
1/11/2016Redmile Group, LlcMajor ShareholderBuy925,000$3.67$3,394,750.00View SEC Filing  
10/1/2015Redmile Group, LlcMajor ShareholderBuy782,592$4.58$3,584,271.36View SEC Filing  
8/25/2015Redmile Group, LlcMajor ShareholderBuy790,000$5.38$4,250,200.00View SEC Filing  
8/10/2015Redmile Group, LlcMajor ShareholderBuy1,048,993$5.80$6,084,159.40View SEC Filing  
3/3/2015Kyle LefkoffDirectorSell70,000$8.00$560,000.00View SEC Filing  
3/2/2015Andrews R RobbinsSVPSell21,576$8.25$178,002.00View SEC Filing  
3/2/2015Ron SquarerCEOSell40,000$8.25$330,000.00View SEC Filing  
9/16/2013Liam RatcliffeDirectorSell1,673,172$6.08$10,172,885.76View SEC Filing  
9/6/2013Liam RatcliffeDirectorSell577,286$5.79$3,342,485.94View SEC Filing  
8/2/2013John R MooreVPSell75,384$7.02$529,195.68View SEC Filing  
7/23/2013John R MooreVPSell5,000$6.50$32,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Array BioPharma (NASDAQ:ARRY)
Latest Headlines for Array BioPharma (NASDAQ:ARRY)
Source:
DateHeadline
americanbankingnews.com logo$22.34 Million in Sales Expected for Array BioPharma Inc. (ARRY) This Quarter
www.americanbankingnews.com - September 20 at 9:24 AM
finance.yahoo.com logoArray BioPharma Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
finance.yahoo.com - September 19 at 4:03 PM
finance.yahoo.com logoArray BioPharma To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 19 at 4:03 PM
americanbankingnews.com logo-$0.22 Earnings Per Share Expected for Array BioPharma Inc. (ARRY) This Quarter
www.americanbankingnews.com - September 18 at 2:28 PM
streetinsider.com logoArray Biopharma (ARRY) Prices 20.93M Shares Common Offering at $10.75/Sh - StreetInsider.com
www.streetinsider.com - September 15 at 9:28 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Halozyme Therapeutics and Array Biopharma
finance.yahoo.com - September 15 at 4:24 PM
finance.yahoo.com logoMirati Skyrockets On Positive Data - Biotech Movers
finance.yahoo.com - September 15 at 4:24 PM
prnewswire.com logoArray BioPharma Announces Pricing of Public Offering of Common Stock - PR Newswire (press release)
www.prnewswire.com - September 15 at 2:42 AM
marketwatch.com logoArray BioPharma shares slide on secondary offering announcement - MarketWatch
www.marketwatch.com - September 14 at 9:40 PM
247wallst.com logoArray BioPharma Slides on Secondary Offering - 24/7 Wall St.
247wallst.com - September 14 at 9:40 PM
finance.yahoo.com logoArray BioPharma Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 14 at 9:40 PM
finance.yahoo.com logoColorado biotech plans $200 million stock offering
finance.yahoo.com - September 14 at 4:38 PM
americanbankingnews.com logoArray BioPharma Inc. (ARRY) Sees Large Increase in Short Interest
www.americanbankingnews.com - September 14 at 1:54 AM
finance.yahoo.com logoArray BioPharma shares slide on secondary offering announcement
finance.yahoo.com - September 13 at 10:15 PM
rttnews.com logoArray BioPharma Inc. (ARRY) Is Falling After Offering Announcement
www.rttnews.com - September 13 at 5:14 PM
finance.yahoo.com logoSteven Cohen Dives Into Array BioPharma
finance.yahoo.com - September 13 at 5:14 PM
finance.yahoo.com logoArray BioPharma Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 13 at 5:14 PM
seekingalpha.com logoArray BioPharma (ARRY) Presents At European Society For Medical Oncology Annual Congress - Slideshow
seekingalpha.com - September 12 at 9:18 PM
americanbankingnews.com logoArray BioPharma Inc. (ARRY) Earns Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - September 12 at 6:28 PM
seekingalpha.com logoMarket Underreacts To Array Biopharma's Groundbreaking Colorectal Cancer Data - Seeking Alpha
seekingalpha.com - September 12 at 4:18 PM
finance.yahoo.com logoArray BioPharma Announces FDA Acceptance For Review Of Binimetinib And Encorafenib New Drug Applications For Patients With Advanced BRAF-mutant Melanoma
finance.yahoo.com - September 12 at 4:18 PM
finance.yahoo.com logoETFs with exposure to Array BioPharma, Inc. : September 12, 2017
finance.yahoo.com - September 12 at 2:02 AM
americanbankingnews.com logoArray BioPharma Inc. (ARRY) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - September 11 at 5:46 PM
seekingalpha.com logoArray BioPharma: Data Updates Point To Continued Upside - Seeking Alpha
seekingalpha.com - September 11 at 3:56 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Array BioPharma and Kura Oncology
finance.yahoo.com - September 11 at 3:56 PM
feeds.benzinga.com logoArray BioPharma And Others Shine At The ESMO 2017 Congress
feeds.benzinga.com - September 11 at 3:06 PM
americanbankingnews.com logoArray BioPharma Inc. (ARRY) Rating Reiterated by J P Morgan Chase & Co
www.americanbankingnews.com - September 11 at 9:04 AM
americanbankingnews.com logoArray BioPharma Inc. (ARRY) Price Target Increased to $15.00 by Analysts at Cantor Fitzgerald
www.americanbankingnews.com - September 11 at 8:22 AM
americanbankingnews.com logoArray BioPharma Inc. (ARRY) Price Target Raised to $15.00 at Stifel Nicolaus
www.americanbankingnews.com - September 11 at 8:10 AM
rttnews.com logoNew Hope For AZN's Old Drug, More About BMY's Opdivo, IMDZ On Watch
www.rttnews.com - September 11 at 1:50 AM
finance.yahoo.com logoPhase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Presented at European Society for Medical Oncology Congress
finance.yahoo.com - September 9 at 3:51 PM
americanbankingnews.com logoArray BioPharma Target of Unusually Large Options Trading (ARRY)
www.americanbankingnews.com - September 9 at 1:30 AM
finance.yahoo.com logoArray BioPharma, Inc. :ARRY-US: Earnings Analysis: Q4, 2017 By the Numbers : September 8, 2017
finance.yahoo.com - September 8 at 9:33 PM
finance.yahoo.com logoArray BioPharma Seems to Be in a New Uptrend
finance.yahoo.com - September 8 at 4:29 PM
finance.yahoo.com logoPhase 3 BEACON CRC Safety Lead-In Results in BRAF-Mutant Colorectal Cancer Presented at European Society for Medical Oncology Congress
finance.yahoo.com - September 8 at 4:29 PM
finance.yahoo.com logoArray Resumes Trades After Unveiling Data In Colon Cancer Trial
finance.yahoo.com - September 8 at 4:29 PM
americanbankingnews.com logoArray BioPharma Inc. (ARRY) Receives "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - September 8 at 4:26 PM
fool.com logoWhat's Behind Array Biopharma Inc.'s 31% Rally in August? - Motley Fool
www.fool.com - September 6 at 9:00 PM
finance.yahoo.com logoWhat's Behind Array Biopharma Inc.'s 31% Rally in August?
finance.yahoo.com - September 6 at 9:00 PM
nasdaq.com logoNotable Wednesday Option Activity: TRTN, DAL, ARRY
www.nasdaq.com - September 6 at 3:57 PM
americanbankingnews.com logoZacks: Analysts Expect Array BioPharma Inc. (ARRY) Will Announce Quarterly Sales of $22.68 Million
www.americanbankingnews.com - September 2 at 3:22 PM
prnewswire.com logoArray Biopharma To Present BEACON CRC Safety Lead-in And COLUMBUS Part 2 Results At European Society For ... - PR Newswire (press release)
www.prnewswire.com - August 30 at 10:58 PM
finance.yahoo.com logoArray Biopharma To Present BEACON CRC Safety Lead-in And COLUMBUS Part 2 Results At European Society For Medical Oncology Congress (ESMO)
finance.yahoo.com - August 30 at 5:16 PM
americanbankingnews.com logoArray BioPharma Inc. (ARRY) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 30 at 9:18 AM
finance.yahoo.com logoArray BioPharma To Present At The 2017 Wells Fargo Healthcare Conference
finance.yahoo.com - August 28 at 4:06 PM
americanbankingnews.com logoJefferies Group LLC Reiterates $9.00 Price Target for Array BioPharma Inc. (ARRY)
www.americanbankingnews.com - August 26 at 8:16 AM
americanbankingnews.com logoArray BioPharma Inc. (ARRY) Raised to Sell at BidaskClub
www.americanbankingnews.com - August 25 at 11:38 PM
seekingalpha.com logoArray Biopharma: - Seeking Alpha
seekingalpha.com - August 25 at 10:44 PM
seekingalpha.com logoArray Biopharma: One Small-Cap Biotech That Should Be In Everyone's Portfolio
seekingalpha.com - August 24 at 4:04 PM
finance.yahoo.com logoArray BioPharma (ARRY) Looks Good: Stock Adds 5.9% in Session
finance.yahoo.com - August 24 at 4:04 PM

Social

Chart

Array BioPharma (ARRY) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff